Researchers at UC Berkeley found that the experimental compound TOFA can increase energy expenditure, improve blood glucose regulation, lower triglycerides and improve markers of fatty liver in obese mice, while reducing body fat without significantly reducing lean mass. The study was published in Science Advances. TOFA promotes the use of fat as an energy source by inhibiting lipid production and activating pathways related to PPARα and PPARδ. Energy expenditure in mice increased by as much as 18%, without an accompanying rise in activity or body temperature. The researchers also tested TOFA in combination with semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, the active ingredient in Mounjaro and Zepbound. The combination groups showed greater improvements in body weight, blood glucose regulation, insulin and triglycerides. All findings currently come from animal studies; TOFA’s efficacy and safety in humans have not yet been established. The team has formed ReRx Therapeutics to advance further research.

Source:ScienceDaily · Read Original